STATUS STUDY: Pilot Open-Label Trial of Intravenous Erenumab in Patients With Status Migrainosus
Latest Information Update: 23 Feb 2022
At a glance
- Drugs Erenumab (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Acronyms STATUS STUDY
- 04 Feb 2022 Status changed from recruiting to withdrawn prior to enrolment.
- 12 Nov 2021 The inclusion criteria has been updated to increase the maximum age limit from 65 years to 70 years, thus including elderly patients as well.
- 07 Sep 2021 Status changed from not yet recruiting to recruiting.